IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (Nasdaq: AGIO) concerning possible violations of federal securities laws.
If you purchased shares of Agios Pharmaceuticals, Inc. and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
During the 2016 American Society of Hematology meeting, Agios presented new information for its AG-348 and AG-519 molecules, which are used to treat pyruvate kinase deficiency. Agios mentioned that a case of Grade 2 thrombocytopenia, which reduces platelets in blood cells, was found in a patient receiving AG-519 and that after a dose of 300 mg, a negative event of drug-related cholestatic hepatitis was found in a bioavailability and food effect study. Following this release, Agios stock dropped, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.